{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:44Z","timestamp":1771997564444,"version":"3.50.1"},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100018542","name":"Sichuan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2019YFS0092"],"award-info":[{"award-number":["2019YFS0092"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2020,10,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hypertension and hypercholesterolemia are two main physiological\nrisk factors of cardiovascular disease, and commonly occur in combination. Multicompound\ncombination therapy is rational for the treatment of concurrent hypertension and\nhypercholesterolemia, while telmisartan and pitavastatin calcium can be used as a potential\ndrug combination.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> The aim of this paper is to study the intestinal absorption and absorption interaction\nof telmisartan and pitavastatin calcium.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>An HPLC method was developed and validated to determine telmisartan and\npitavastatin calcium in intestinal perfusate simultaneously. The in situ single-pass\nperfusion in rats was utilized to investigate the effects of concentrations, intestinal segment\n(duodenum, jejunum, ileum and colon) and co-administrated drugs on absorption.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The effective permeability coefficient and the absorption rate constant of telmisartan\nwere higher in the duodenum as compared to other intestinal segments. However, the\nintestinal absorption of pitavastatin calcium was not segmental dependent. The effective\npermeability coefficient and absorption rate constant have no significant difference among\nthree concentrations of telmisartan, pitavastatin calcium individually and their combination.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The results showed that telmisartan and pitavastatin calcium were transported\npassively, and telmisartan and pitavastatin calcium could be absorbed well in all intestinal\nsegments. The intestinal absorption parameters revealed the absence of any intestinal absorption\ninteraction when co-administered.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Lay Summary:<\/jats:title>\n<jats:p>Co-administration of telmisartan and pitavastatin calcium can provide a\npotential therapeutic strategy for the treatment of concurrent hypertension and hypercholesterolemia.\nWe are investigating the intestinal interaction of these two drugs in rats using\nthe developed HPLC method and in situ single-pass perfusion technology. We will calculate\nsome parameters after administrating two types of drugs either separately or together,\nwhich help reflect changes regarding intestinal absorption and penetration. Compared with\ntelmisartan and pitavastatin calcium administrated separately, if parameters significantly\nchange after co-administration, it proves the existence of the intestinal interactions. Moreover,\nthe results might contribute to clinic drug monitoring.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211738508666200607181727","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T16:26:12Z","timestamp":1591547172000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous Determination of Telmisartan and Pitavastatin Calcium in Intestinal Perfusate by HPLC: Application to Intestinal Absorption Interaction Study"],"prefix":"10.2174","volume":"8","author":[{"given":"Junying","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Sichuan Institute for Food and Drug Control, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Fu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1161\/CIRCULATIONAHA.115.016021","volume":"132","author":"Roth G.A.","year":"2015","unstructured":"Roth G.A.; Nguyen G.; Forouzanfar M.H.; Mokdad A.H.; Naghavi M.; Murray C.J.; Estimates of global and regional premature cardiovascular mortality in 2025. Circulation 2015,132(13),1270-1282","journal-title":"Circulation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/01.HYP.37.2.774","volume":"37","author":"Rodriguez-Porcel M.","year":"2001","unstructured":"Rodriguez-Porcel M.; Krier J.D.; Lerman A.; Combination of hypercholesterolemia and hypertension augments renal function abnormalities. Hypertension 2001,37(2 Pt 2),774-780","journal-title":"Hypertension"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4070\/kcj.2015.45.3.225","volume":"45","author":"Jang J.Y.","year":"2015","unstructured":"Jang J.Y.; Lee S.H.; Kim B.S.; Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. Korean Circ J 2015,45(3),225-233","journal-title":"Korean Circ J"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40256-016-0175-2","volume":"16","author":"Bertrand M.E.","year":"2016","unstructured":"Bertrand M.E.; Vlachopoulos C.; Mourad J.J.; Triple Combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs 2016,16(4),241-253","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0140-6736(05)17833-7","volume":"365","author":"Jackson R.","year":"2005","unstructured":"Jackson R.; Lawes C.M.M.; Bennett D.A.; Milne R.J.; Rodgers A.; Treatment with drugs to lower blood pressure and blood cholesterol based on an individual\u2019s absolute cardiovascular risk. Lancet 2005,365(9457),434-441","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009868","volume":"4","author":"de Cates A.N.","year":"2012","unstructured":"de Cates A.N.; Farr M.R.B.; Wright N.; Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Db Syst Rev 2012,4(4)","journal-title":"Cochrane Db Syst Rev"},{"key":"ref=7","first-page":"136","volume":"18","author":"Molinengo L.","year":"1968","unstructured":"Molinengo L.;  Minerva Nipiol  [The pill: lights and shadows]1968,18(5),136-139","journal-title":"Minerva Nipiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.aogh.2013.12.008","volume":"80","author":"Wiley B.","year":"2014","unstructured":"Wiley B.; Fuster V.; The concept of the polypill in the prevention of cardiovascular disease. Ann Glob Health 2014,80(1),24-34","journal-title":"Ann Glob Health"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","volume":"326","author":"Wald N.J.","year":"2003","unstructured":"Wald N.J.; Law M.R.; A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003,326(7404),1419","journal-title":"BMJ"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/CIRCOUTCOMES.111.963637","volume":"5","author":"Yusuf S.","year":"2012","unstructured":"Yusuf S.; Pais P.; Sigamani A.; Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012,5(4),463-471","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1177\/2047487314530382","volume":"22","author":"Patel A.","year":"2015","unstructured":"Patel A.; Cass A.; Peiris D.; A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015,22(7),920-930","journal-title":"Eur J Prev Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/VHRM.S7857","volume":"6","author":"Galzerano D.","year":"2010","unstructured":"Galzerano D.; Capogrosso C.; Di Michele S.; New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010,6(1),113-133","journal-title":"Vasc Health Risk Manag"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/11591190-000000000-00000","volume":"11","author":"da Silva P.M.","year":"2011","unstructured":"da Silva P.M.; Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs 2011,11(2),93-107","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1567-5688(10)71064-3","volume":"11","author":"Betteridge J.","year":"2010","unstructured":"Betteridge J.; Pitavastatin - results from phase III","journal-title":"Atheroscler Suppl"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2015.06.005","volume":"762","author":"Xu C.","year":"2015","unstructured":"Xu C.; Fang D.; Chen X.; Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs. Eur J Pharmacol 2015,762,364-371","journal-title":"Eur J Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/jps.2600750203","volume":"75","author":"Schurgers N.","year":"1986","unstructured":"Schurgers N.; Bijdendijk J.; Tukker J.J.; Crommelin D.J.; Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ. J Pharm Sci 1986,75(2),117-119","journal-title":"J Pharm Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1023\/A:1016065715308","volume":"13","author":"Fagerholm U.","year":"1996","unstructured":"Fagerholm U.; Johansson M.; Lennern\u00e4s H.; Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996,13(9),1336-1342","journal-title":"Pharm Res"},{"key":"ref=18","first-page":"1805","volume":"32","author":"Shen J.","year":"2012","unstructured":"Shen J.; Wang-Chun D.U.; Song Z.J.; In situ intestinal absorption of telmisartan and the effect of coadministrated drugs on its absorption in rats. Zhongguo Yiyuan Yaoxue Zazhi 2012,32(22),1805-1808","journal-title":"Zhongguo Yiyuan Yaoxue Zazhi"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1177\/147323000903700602","volume":"37","author":"Burnier M.","year":"2009","unstructured":"Burnier M.; Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 2009,37(6),1662-1679","journal-title":"J Int Med Res"},{"key":"ref=20","first-page":"1624","volume":"41","author":"Shen J.","year":"2006","unstructured":"Shen J.; Jiao Z.; Li Z.; Transport characteristics of telmisartan in human intestinal cell line Caco-2. Zhongguo Yaoxue Zazhi 2006,41(21),1624-1627","journal-title":"Zhongguo Yaoxue Zazhi"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1021\/mp800088f","volume":"6","author":"Dahan A.","year":"2009","unstructured":"Dahan A.; Amidon G.L.; Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 2009,6(1),19-28","journal-title":"Mol Pharm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/dmd.31.4.373","volume":"31","author":"Tam D.","year":"2003","unstructured":"Tam D.; Tirona R.G.; Pang K.S.; Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 2003,31(4),373-383","journal-title":"Drug Metab Dispos"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1385\/1-59259-800-5:065","author":"Jeong E.J.","year":"2004","unstructured":"Jeong E.J.; Liu Y.; Lin H.; Hu M.;  In situ single-pass perfused rat intestinal model for absorption and metabolism 2004,65-76","journal-title":"In situ single-pass perfused rat intestinal model for absorption and metabolism"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejps.2008.10.013","volume":"36","author":"Dahan A.","year":"2009","unstructured":"Dahan A.; West B.T.; Amidon G.L.; Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci 2009,36(2-3),320-329","journal-title":"Eur J Pharm Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.fitote.2015.06.014","volume":"105","author":"Zeng X.Y.","year":"2015","unstructured":"Zeng X.Y.; Dong S.; He N.N.; Jiang C.J.; Dai Y.; Xia Y.F.; Comparative pharmacokinetics of arctigenin in normal and type 2 diabetic rats after oral and intravenous administration. Fitoterapia 2015,105,119-126","journal-title":"Fitoterapia"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182585\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T19:06:28Z","timestamp":1615143988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182585\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211738508666200607181727","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}